Canadian Hospital Specialties Limited’s Post

This content is intended for U.S. audiences only. Antibody-drug conjugates (ADCs) continue to evolve #Oncology treatment for #CancerPatients.(1) #ADCs are emerging as alternatives to chemotherapy for mBC and mNSCLC.(2-3) ADCs are specifically designed to selectively deliver potent cytotoxic agents to tumor cells, with the intention to spare healthy cells.(4) Understanding how the 3 components of ADCs—antibody, linker, and payload—work together is crucial in appreciating the difference they can bring to #CancerTherapy.(2) Learn more at ADCevolution.com #ASCO2024 #AZUS American Society of Clinical Oncology (ASCO)

Imaging biomarkers are an essential part of measuring the efficacy of potential new treatments in oncology studies. The RECIST protocol has been the predominant imaging-based oncology response evaluation criteria for a quarter of a century and has many benefits. However, it also has limitations and now is the time to consider complimentary, better ways of tracking changes in tumours during clinical trials. Tumour growth rate modelling is one such methodology. Read our whitepaper to discover more about this approach, its advantages over conventional oncological assessment criteria, and the considerations for using TGR modelling in your oncology research. https://ow.ly/Vc2L50TT4O0 #medicalimaging #oncology

Imaging biomarkers are an essential part of measuring the efficacy of potential new treatments in oncology studies. The RECIST protocol has been the predominant imaging-based oncology response evaluation criteria for a quarter of a century and has many benefits. However, it also has limitations and now is the time to consider complimentary, better ways of tracking changes in tumours during clinical trials. Tumour growth rate modelling is one such methodology. Read our whitepaper to discover more about this approach, its advantages over conventional oncological assessment criteria, and the considerations for using TGR modelling in your oncology research. https://ow.ly/Vc2L50TT4O0 #medicalimaging #oncology

Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach - Zhen Su, MD MBA https://lnkd.in/dJadC2be Marengo Therapeutics ATP (Apple Tree Partners) ESMO - European Society for Medical Oncology #Cancer #ESMO2024 #Medicine #Health #CancerTreatment #Oncology #OncoDaily

Check out my team's latest work in our recently published #liquidbiopsy market report: https://lnkd.in/gMqPUZqG While this landscape overview is non-exhaustive*, it is clear that the #LBx market remains dynamic with opportunity for growth.

Patient-derived xenograft organoids- Tumirgraft3D models to study Immuno-oncology study- with Champions CO-CULTURE models - design your preclinical study with the most clinically relevant models - that mimics clinical populations (including pre-treatments and high level -ionic characterizations). Listen to the webinar and start your new study today. #pdx #exvivo #tumorpdx #pdxo #IO #coculture #cart #TILs #immunecheckpointinhibitors

Our updated #liquidbiopsy (LBx) report has been published! The LBx market remains dynamic, with multiple opportunities for significant clinical impact and commercial growth ahead. Find more information about the report here: https://bit.ly/4deHFrW Feel free to reach out if you'd like to discuss the liquid biopsy and/or precision oncology landscape! #precisionmedicine #oncology #cancerresearch #earlydetection #ctDNA #multiomics #MRD #MCED #DeciBio

🚨 Did You Miss Our Webinar? Now Watch It On-Demand! 🚨 If you were unable to attend our recent webinar, "How to Design a Successful 3D Tumor Model Co-Culture Study," don’t worry! You can now access the full recording at your convenience. Watch the webinar : https://hubs.li/Q02NTF7p0 Catch up on this informative session and enhance your oncology research with advanced ex vivo 3D tumor model co-culture methodologies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture

A groundbreaking study has shown that bromelain significantly boosts the effectiveness of HIPEC in treating appendiceal cancer by aiding mucin dissolution. When used with NAC, bromelain enhances the cytotoxicity of HIPEC drugs, suggesting a potential revolution in managing peritoneal carcinomatosis. These findings could greatly influence future surgical protocols and patient outcomes. #Oncology #SurgicalInnovation #CancerResearch

A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC - Elisa Agostinetto JAMA Oncology OncoAlert #BreastCancer #Research #Cancer #HER2E #JAMAOncology #OncoDaily #Oncology #PCR #TumorSubtypes